MYOD1 and familial dilated cardiomyopathy: Further studies using other DCM models such as transgenic murine models lacking γ-sarcoglycan [45], dystrophin and MyoD [46], or animal models which have undergone transverse aortic constriction to induce DCM would be required to assess the potential therapeutic benefits of HMGB1 fragment for DCM patients.